NEW YORK, July 9 – Secant Technologies will take over the further development and marketing of Incyte Genomics’ Genomics Knowledge Platform (GKP), a suite of data integration and analysis software applications, the companies said Monday.
The arrangement calls for Secant to exclusively license the right to further develop and market the software platform. Over the past 20 months, the two companies have collaborated on the software development. In addition, Incyte said it made an undisclosed equity investment in Secant, and the two companies will also work together to provide support services to customers of the platform.
The platform, launched last November, provides tools for researchers to integrate and analyze a wide range of data, from gene sequence, expression, polymorphism, proteomic, and other functional data. The object model-based platform also uses IBM’s DiscoveryLink data integration software.
"We constructed the Genomics Knowledge Platform to extend data integration beyond genomics to all science-based information types, including chemical and clinical. It's only natural, therefore, that the universal open architecture which allows for collaboration with other information providers and software creators can be better served by a company like Secant whose focus is software and data integration," Roy Whitfield, CEO of Incyte, said in a statement.
Incyte will continue to promote and market the platform to its present and prospective customers, Whitfield added.